Sunday, January 16, 2022 1:48:34 PM
It feels like lately we’re having the wrong conversation. The debate shouldn’t be whether Dr. Missling is doing a good job, it should be whether the A273 works.
Does anyone remember back in 2015, 2016, when people like Martin Shkreli, Jean Fonteneau, Adam Feuerstein used to attack the science? This was easy to do then because there was so little data, but these days those who do not believe Anavex will succeed are going after the company’s leadership. Again, we don’t have much of a track record for how Dr. Missling will perform — he may be the best CEO to bring the drug to market but the wrong person for the job to market it successfully. We’ll see.
My point is that whether Dr. Missling is doing a good job is not the conversation that we should be having. Let’s get back to discussing the science. I want to hear from those with knowledge why A273 will work, or won’t. There are a few posters here who continue to do that, but I miss the likes of Dadofmarcmax and others who were able to contribute to meaningful debate — not whether Dr. Missling should be tarred and feathered because he’s a few months behind reporting data.
Louis CK has a brilliant comedy bit about how everything is wonderful and nobody’s happy. He used the example of the WiFi on an airplane not working — forgetting the fact you’re in a metal tube flying 500 mph across the country when just 125 years ago the same journey meant forging the river and hoping your family won’t die of dysentery.
How many people complaining about Rett delays invested in AVXL because of Rett Syndrome? How many investors here had even heard of Rett before they invested in AVXL?
Dr. Missing is setting this up to give the best chance for success. It’s much easier to convince the FDA to approve a rare pediatric disease than to approve a novel Alzheimer’s drug. If/when A273 is approved for Rett, Anavex will be submitting its other trials with a drug that’s already been approved, and it will have the priority voucher to further accelerate the review process.
I’d rather take my time with this plan than doing “sneak peaks” or trying to rush everything through just to meet an arbitrary deadline. Going forward I’d be surprised if Dr. Missling offers any timeline at all, and I’ll bet he gets attacked for that.
Dr. Missling isn’t perfect and I’ve called his motives into question in the past — I don’t like the idea of blank check preferred shares because the downside to poison pill protection means that it’s harder for shareholders to replace the CEO should we want to down the road.
But to criticize Dr. Missling because he’s late on his estimated timeline — during a pandemic when everything came to a sudden halt — and to do so just three weeks into Q1 is absurd. Impatient traders are the only ones who want to cash out ASAP, and I’m grateful that Dr. Missling isn’t pandering to them.
Those who say they care about those suffering — we all do. How many could also say with a straight face that they’d be okay with a competitor beating AVXL to market if that’s what it took to end suffering quickly?
Sorry for the long rant — but this will be my last post here for a while, until the conversation is steered back toward the science and odds for success, because ultimately that’s the only thing that matters right now.
Best of luck and stay safe!
Recent AVXL News
- Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference • GlobeNewswire Inc. • 06/20/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:30:10 AM
- Anavex Life Sciences Announces Expansion of Leadership Team • GlobeNewswire Inc. • 05/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:35:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:30 PM
- Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL • PR Newswire (US) • 04/26/2024 09:45:00 AM
- Contact The Gross Law Firm by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL) • PR Newswire (US) • 04/19/2024 09:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences Lawsuit - AVXL • PR Newswire (US) • 04/16/2024 09:45:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/12/2024 09:45:00 AM
- Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference • GlobeNewswire Inc. • 04/11/2024 11:30:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/09/2024 09:45:00 AM
- Anavex Life Sciences Corporation Class Action: The Gross Law Firm Reminds Anavex Life Sciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 13, 2024 - AVXL • PR Newswire (US) • 04/05/2024 09:45:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 04/02/2024 09:45:00 AM
- Lost Money on Anavex Life Sciences Corporation(AVXL)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm • PR Newswire (US) • 03/29/2024 09:45:00 AM
- Investors who lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 03/26/2024 09:45:00 AM
- Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 03/25/2024 11:30:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM